Heather Sell

Heather Sell

Auto-generated profile, based on publicly available information

Heather Sell

Pfizer Inc., New York, NY

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 July 2024 in Journal of Medical Economics
Verified
Journal Article
Open access
JJJennifer Judy
Jennifer Judy
AYAlon Yehoshua
Alon Yehoshua
JGJulie Gouveia-Pisano
Julie Gouveia-Pisano
RBRichard A. Brook
Richard A. Brook
NKNathan Kleinman
Nathan Kleinman
HSHeather Sell
Heather Sell
ObjectivesThis study investigates the utilization of work absence benefits among United States (US) employees diagnosed with COVID-19, examining frequency, duration, cost, and types of work loss benefits used.MethodsThis retrospective analysis of the Workpartners Research Reference Database (RRDb) included employees eligible for short- and long-term disability (STD and LTD employer-sponsored benefits, respectively), and other paid work absence benefits from 2018-2022. Workpartners RRDb includes over 3.5 million employees from over 500 self-insured employers across the US. Employees were identified by codes from adjudicated medical and disability claims for COVID-19 (2020-2022) and influenza, as well as prescription claims for COVID-19. Associated payments were quantified for each absence reason.ResultsApproximately 1 million employees were eligible for employer-sponsored paid leave benefits between January 2018 and December 2022. The mean age was 37 years (22% >50 years), and 49.9% were female. COVID-19 was the 2nd most common reason for an STD claim (6.9%) and 13th for an LTD claim (2020-2022). The mean duration for COVID-19 STD claims was 24 days (N = 3731, mean claim=$3477) versus 10 days for influenza (N = 283, mean claim=$1721). The mean duration for an LTD claim for COVID-19 was 153 days (N = 24, mean claim=$19,254). Only 21.5% of employees with STD claims in the COVID-19 cohort had prior COVID-19-associated medical or pharmacy claims; over half (range 53%-61%) had documented high risk factors for severe COVID-19.ConclusionCOVID-19 and influenza have the potential to cause work loss in otherwise healthy employees. In this analysis, COVID-19 was the second most frequent reason for an STD claim at the start of the pandemic and remained high (ranked 5th) in 2022. These results highlight the impact of COVID-19 on work loss beyond the acute phase. Comprehensively evaluating work loss implications may help employers prioritize strategies, such as vaccinations and timely treatments, to mitigate the impact of COVID-19 on employees and their companies.

5 October 2021 in Journal of Occupational and Environmental Medicine
Verified
Journal Article
Open access
STSheena Thakkar
Sheena Thakkar
BGBrian Gifford
Brian Gifford
HSHeather Sell
Heather Sell
PSPatricia Schepman
Patricia Schepman
RRRebecca L Robinson
Rebecca L Robinson
BEBirol Emir
Birol Emir
Objectives: Examine short-term disability (STD) and workers’ compensation (WC) associated leave and wage replacements, and overall direct healthcare payments, among employees with osteoarthritis (OA) versus other chronically painful conditions; quantifying the impact of opioid use. Methods: Analysis of employees with more than or equal to two STD or WC claims for OA or pre-specified chronically painful conditions (control) in the IBM MarketScan Research Databases (2014 to 2017). Results: The OA cohort (n = 144,355) had an estimated +1.2 STD days, +$152 STD payments, and +$1410 healthcare payments relative to the control cohort (n = 392,639; P < 0.001). WC days/payments were similar. Differences were partially driven by an association between opioid use, increased STD days/payments, and healthcare payments observed in pooled cohorts (P < 0.001). Conclusions: OA is associated with high STD days/payments and healthcare payments. Opioid use significantly contributes to these and this should be considered when choosing treatment.

10 April 2025 in Journal of Occupational and Environmental Medicine
Verified
Journal Article
Open access
HSHeather Sell
Heather Sell
JGJulie Gouveia-Pisano
Julie Gouveia-Pisano
SSSean Jd Sullivan
Sean Jd Sullivan
DLDeborah Love
Deborah Love
BDBonnie DeLor
Bonnie DeLor
HSHeather Somand
Heather Somand
Objective: Quantify the impact of uterine fibroids (UF) on work productivity among employed women in the US. Methods: Adult women working in healthcare who reported either being diagnosed with or having uterine fibroid symptoms completed a survey incorporating the Work Productivity and Activity Impairment Questionnaire specific for Uterine Fibroids. Results: Among 67 respondents (mean age 43.2 years; 43% in executive/professional roles), 84% reported receiving a UF diagnosis from a healthcare provider; 16% reported symptoms consistent with UF. Forty-nine (73%) respondents reported a mean overall work impairment score of 33% during the past week due to UF driven by presenteeism (28%) relative to absenteeism (6%). Lost productivity costs were estimated at $387/week. Conclusions: Women with UF symptoms report substantial lost productivity, driven primarily by impairment while at work, which also has economic implications.